AMGN

Business Context and Reporting Period

Company: Amgen Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2001
Overview: Amgen is a global biotechnology company discovering, developing, and marketing human therapeutics. Key products include EPOGEN (anemia), NEUPOGEN (neutropenia), Aranesp (anemia), and Kineret (rheumatoid arthritis). The company operates manufacturing facilities in the U.S., Puerto Rico, and the Netherlands, with a global sales force.

Key Financial Metrics (Year Ended Dec 31, 2001)

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 10.6% driven by a 10% increase in product sales. EPOGEN/Aranesp combined sales rose 10% to $2,150.0 million, and NEUPOGEN sales increased 10% to $1,346.4 million.
• Net Income Decline: Despite revenue growth, net income decreased slightly due to significant non-recurring charges. "Other items, net" included a $203.1 million charge for terminating collaboration agreements (including Praecis) and a $39.5 million inventory write-off.
• Liquidity Position: Cash and cash equivalents surged to $689.1 million from $226.5 million, bolstered by strong operating cash flows and stock option exercises ($277.7 million).
• Capital Allocation: The company repurchased 12.7 million shares of common stock for $737.5 million. Capital expenditures were $441.8 million.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• New Product Launches: Aranesp was approved in the U.S. and EU in late 2001. Neulasta (pegfilgrastim) received FDA approval in January 2002 with a planned April 2002 launch. Kineret was approved in November 2001 for rheumatoid arthritis.
• Merger with Immunex: In December 2001, Amgen signed a definitive agreement to acquire Immunex Corporation for an estimated $17.6 billion (stock and cash). The transaction is expected to close in the second half of 2002, subject to regulatory approval.
• Debt Financing: In February 2002, Amgen announced an agreement to issue $3.5 billion in 30-year zero-coupon convertible senior notes. Proceeds are expected to fund share repurchases and general corporate purposes.
• Future Drivers: Growth is expected to be driven by Aranesp in new markets, patient population growth in dialysis, and the launch of Neulasta. Management notes that Neulasta may cannibalize NEUPOGEN sales as providers transition to the single-dose product.

Risks and Contingencies

• Reimbursement: Sales of EPOGEN and NEUPOGEN are heavily dependent on government reimbursement (Medicare/ESRD Program) and private payors. Changes in reimbursement rates could materially impact sales.
• Legal Proceedings: Ongoing patent litigation with Transkaryotic Therapies and Aventis regarding erythropoietin patents (appeal pending). Arbitration with Johnson & Johnson regarding "spillover" sales of Epoetin alfa commenced in January 2002.
• Merger Risks: The Immunex merger faces regulatory hurdles (FTC approval) and integration risks. Failure to close could result in a $475 million termination fee.
• Competition: Intense competition exists in anemia, neutropenia, and rheumatoid arthritis markets from large pharmaceutical companies and biotechnology firms.

Investor Verification Checklist

• Merger Status: Verify the regulatory approval status and expected closing date of the Immunex acquisition.
• Convertible Notes: Confirm the final terms and closing of the $3.5 billion convertible note offering announced in February 2002.
• Product Cannibalization: Monitor early sales data for Neulasta to assess the rate of transition from NEUPOGEN in the U.S. market.
• Legal Outcomes: Track the appellate court decision in the Transkaryotic Therapies/Aventis patent litigation and the outcome of the Johnson & Johnson arbitration.
• Reimbursement Policy: Watch for changes in Medicare ESRD Program reimbursement rates that could affect EPOGEN and Aranesp revenue.